Saturday 17 October 2026 Export NEUP’s income statement to Excel — free account

Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.

3.30 0.01 −0.30%

Follow NEUP

Alert me

Market cap: $17.9M
P/E: 0.0×
Fwd P/E: −1.9×
Dividend yield: —
F-score: n/a
Altman Z: −7.55
Beneish M: 831.96
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 17.91

Revenue 15.66

Net Income (13.45)

Free Cash Flow (12.35)

Net Debt (19.87)

Current Ratio 27.85

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.85)

P/S ratio 0.91

P/B ratio 0.58

Past 5Y EPS Growth —

This Y EPS Growth 40.29%

Next Y EPS Growth (1.23%)

Next Y revenue growth 788.06%

Next 5Y EPS Growth (13.71%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 12.70%

10-year low 10-year high

P/B against its own 10 years 29.10%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	12	13	14	20
Receivables	0	0	0	1
Inventory	—	—	—	—
Other	—	—	—	—
	13	13	15	21

	2023	2024	2025	2026
Payables	1	2	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	4	4	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.07%	83.09%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(7.11%)	3.78%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	1
’25	15	0	—	1	16
’23	—	0	—	—	0
’22	—	0	—	0	0
’20	—	0	—	0	0
’19	—	1	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(4)	(6)	(3)	1	(12)
’25	(4)	(3)	11	(4)	0
’24	(4)	(5)	(2)	(3)	(15)
’23	—	(6)	—	(14)	(15)
’22	—	(9)	—	(16)	(16)
’21	—	(1)	—	(6)	(6)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(4)	(6)	(3)	1	(12)
’25	(4)	(3)	11	(4)	0
’24	(4)	(5)	(2)	(3)	(15)
’23	—	(6)	—	(14)	(15)
’22	—	(9)	—	(16)	(16)
’21	—	(1)	—	(6)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(4.41)	0.41	(0.09)	(0.95)	(3.06)
’25	(0.62)	(1.23)	6.55	(5.79)	(0.23)
’24	(7.90)	—	(2.83)	(2.57)	(18.61)
’23	—	(0.01)	—	(0.01)	(29.05)
’22	—	(0.01)	—	(0.01)	(31.33)
’21	—	0.00	—	(0.01)	(18.00)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	—	144.60	51.00	11.16	2.12	2.90	3.19	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	—	264.00	165.12	92.52	18.00	21.40	5.53
People
People	Employees	—	—	—	—	7	7	8	8	8	1
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	1.96	1.17
Income, $m
Income, $m	Revenue	14	3	0	0	—	0	0	—	16	1
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	100.00	—	100.00	100.00
	EBT	(10)	(24)	(12)	(6)	(7)	(16)	(22)	(16)	(1)	(14)
	EBT margin, %	(71.15)	(874.26)	(2,428.24)	(19,212.42)	0.00	(8,324.93)	(145,411.49)	0.00	(5.35)	(1,157.48)
	Net income	0	(19)	(7)	(4)	(6)	(16)	(21)	(15)	0	(13)
	Depreciation	1	1	1	2	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	4.47	0.90	0.15	0.01	0.00	0.31	0.02	0.00	9.64	0.27
	Earnings	(0.01)	(0.03)	(0.01)	(0.01)	(13.93)	(31.33)	(29.05)	(18.61)	(0.23)	(3.06)
	Cash flow	(0.06)	(4.79)	(3.22)	(0.76)	(15.61)	(25.20)	(21.54)	(17.64)	0.05	(2.81)
	Capex	0.00	0.00	0.00	0.00	0.07	0.20	0.00	0.00	0.00	0.00
	Free cash flow	(0.06)	(4.79)	(3.22)	(0.76)	(15.54)	(25.00)	(21.54)	(17.64)	0.05	(2.81)
	Book value	9.81	4.08	3.47	2.50	98.55	65.93	32.38	21.02	11.71	5.60
	Shares, m	3	3	3	3	0	1	1	1	2	4
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	0.00	0.00	—	0.00	0.00
	P/S	558.54	558.54	558.54	558.54	—	1,463.61	574.69	—	0.74	1.23
	P/B	21.54	21.54	21.54	21.54	—	15.27	0.00	—	0.61	0.78
	EV/Sales	543.25	543.25	543.25	543.25	—	1,408.25	543.36	—	(0.12)	0.02
	EV/FCF	(80.32)	(80.32)	(80.32)	(80.32)	—	(19.13)	(4.49)	—	(8.12)	(0.02)
Cash, $m
Cash, $m	Operating cash flow	0	(15)	(11)	(3)	(6)	(16)	(15)	(15)	0	(12)
	Capex	0	0	0	0	0	0	—	—	—	—
	Free cash flow	0	(15)	(11)	(3)	(6)	(16)	(15)	(15)	0	(12)
Balance, $m
Balance, $m	Working capital	31	17	8	0	21	28	11	9	11	20
	Total debt	14	16	13	8	1	0	0	—	—	—
	Net debt	(19)	(3)	3	5	(21)	(24)	(12)	(13)	(14)	(20)
	Shareholders’ equity	31	13	12	9	36	41	22	17	19	25
Returns, %
Returns, %	ROA	(9.20)	(77.11)	(16.91)	(15.95)	(20.26)	(35.91)	(56.31)	(55.12)	(1.31)	(46.95)
	ROIC	0.00	0.00	0.00	0.00	(24.03)	(57.33)	(138.68)	(229.05)	(14.97)	(217.17)
	ROE	(23.77)	(85.08)	(60.13)	(48.22)	(29.37)	(41.08)	(67.56)	(78.44)	(2.03)	(61.70)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2025 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATYR aTyr Pharma, Inc.	$18.0M	— (loss-making)	— (loss-making)	−90.75% (below 0%: shrinking)	n/m	+32.22% (above 0%: growing)	100.00%	0.00%	Compare
NEUP Neuphoria Therapeutics Inc.	$17.9M	— (loss-making)	— (loss-making)	−107.32% (below 0%: shrinking)	n/m	+133.86% (above 0%: growing)	100.00%	0.00%
JSPR Jasper Therapeutics, Inc.	$17.7M	— (loss-making)	—	—	n/m	+55.74% (above 0%: growing)	0.00%	0.00%	Compare
ANEB Anebulo Pharmaceuticals, Inc.	$17.6M	— (loss-making)	—	—	n/m	+6.58% (above 0%: growing)	—	0.00%	Compare
ACGN Aceragen, Inc.	$17.1M	— (loss-making)	— (loss-making)	+2,394.95% (above 0%: growing)	n/m	−115.67% (below 0%: shrinking)	100.00%	(834.33%)	Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR	$17.0M	—	—	—	—	−137.75% (below 0%: shrinking)	—	—	Compare
DYAI Dyadic International Inc.	$16.8M	— (loss-making)	— (loss-making)	−0.57% (below 0%: shrinking)	n/m	−1,298.54% (below 0%: shrinking)	(2.39%)	(213.73%)	Compare
PBM Psyence Biomedical Ltd.	$16.5M	0.2×	—	—	n/m	−707.20% (below 0%: shrinking)	—	0.00%	Compare
TCRX TScan Therapeutics, Inc.	$16.2M	— (loss-making)	— (loss-making)	−65.83% (below 0%: shrinking)	n/m	+18.95% (above 0%: growing)	100.00%	(2,901.33%)	Compare
Median of peers	$17.1M	—	—	−33.20%	—	−54.54%	100.00%	0.00%

All 614 Biotechnology stocks →

Neuphoria Therapeutics Inc. (NEUP) key facts

Concern: Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025.
Neuphoria Therapeutics Inc. (NEUP) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, NEUP traded at $3.30, a market capitalization of $17.9 million.
Return on equity was −61.7% and debt-to-equity 0.00.
Its Altman Z-score is −7.55 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.